The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
MoonLake Immunotherapeutics (NASDAQ: MLTX) closed the day trading at $14.07 down -3.70% from the previous closing price of $14.61. In other words, the price has decreased by -$3.70 from its previous closing price. On the day, 2.0 million shares were traded. MLTX stock price reached its highest trading level at $14.584 during the session, while it also had its lowest trading level at $13.87.
Ratios:
For a better understanding of MLTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.50 and its Current Ratio is at 8.50. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 08 ’25 when Santos da Silva Jorge sold 130,000 shares for $15.08 per share. The transaction valued at 1,960,400 led to the insider holds 2,948,577 shares of the business.
Santos da Silva Jorge sold 70,000 shares of MLTX for $1,014,300 on Dec 09 ’25. The Chief Executive Officer now owns 2,878,577 shares after completing the transaction at $14.49 per share. On Dec 08 ’25, another insider, Reich Kristian, who serves as the Chief Scientific Officer of the company, sold 130,000 shares for $15.08 each. As a result, the insider received 1,960,400 and left with 72,908 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLTX now has a Market Capitalization of 996822912 and an Enterprise Value of 593854912.
Stock Price History:
The Beta on a monthly basis for MLTX is 1.20, which has changed by -0.72594464 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, MLTX has reached a high of $62.75, while it has fallen to a 52-week low of $5.95. The 50-Day Moving Average of the stock is 23.86%, while the 200-Day Moving Average is calculated to be -61.68%.
Shares Statistics:
Over the past 3-months, MLTX traded about 5.11M shares per day on average, while over the past 10 days, MLTX traded about 1908860 shares per day. A total of 63.70M shares are outstanding, with a floating share count of 62.77M. Insiders hold about 11.40% of the company’s shares, while institutions hold 60.63% stake in the company. Shares short for MLTX as of 1764288000 were 4270493 with a Short Ratio of 0.84, compared to 1761868800 on 4907886. Therefore, it implies a Short% of Shares Outstanding of 4270493 and a Short% of Float of 11.9799994.
Earnings Estimates
. The current market rating for MoonLake Immunotherapeutics (MLTX) reflects the collective analysis of 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.68 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$3.46 and -$3.69 for the fiscal current year, implying an average EPS of -$3.58. EPS for the following year is -$3.58, with 10.0 analysts recommending between -$1.83 and -$4.36.
